Temozolomide in Treating Patients With Invasive Pituitary Tumors

This study has been withdrawn prior to enrollment.
(funding term ended)
Sponsor:
Collaborator:
Information provided by:
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00601289
First received: January 25, 2008
Last updated: July 27, 2012
Last verified: July 2012

January 25, 2008
July 27, 2012
December 2009
October 2010   (final data collection date for primary outcome measure)
  • Change from baseline of pituitary tumor control as assessed by MRI at 3, 6, 9, and 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Change in Tumor response rate (complete response or partial response) from baseline as assessed by RECIST criteria at 3, 6, 9, and 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Rebound tumor growth as assessed by MRI at 6 months after completion of treatment [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Pituitary tumor control as assessed by MRI at baseline and at 3, 6, 9, and 12 months [ Designated as safety issue: No ]
  • Tumor response rate (complete response or partial response) as assessed by RECIST criteria at baseline and at 3, 6, 9, and 12 months [ Designated as safety issue: No ]
  • Rebound tumor growth as assessed by MRI at 6 months after completion of treatment [ Designated as safety issue: No ]
  • Duration of tumor response as assessed by RECIST criteria at baseline and at 3, 6, 9, and 12 months [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00601289 on ClinicalTrials.gov Archive Site
  • Biochemical control as assessed by measurement of hormones secreted in excess by the pituitary tumor at baseline, at 3, 6, 9, and 12 months during treatment, and then at 2 months after completion of treatment [ Time Frame: 14 months ] [ Designated as safety issue: No ]
  • Pituitary function as assessed by standard pituitary function tests at baseline and at 6 months and 12 months [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Safety and tolerability of temozolomide as assessed by NCI CTC v2.0 at screening, baseline, and then monthly until study completion [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Overall quality of life as assessed by Karnofsky performance status questionnaire periodically during study [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Biochemical control as assessed by measurement of hormones secreted in excess by the pituitary tumor at baseline, at 3, 6, 9, and 12 months during treatment, and then at 2 months after completion of treatment [ Designated as safety issue: No ]
  • Pituitary function as assessed by standard pituitary function tests at baseline and at 6 months and 12 months [ Designated as safety issue: No ]
  • Safety and tolerability of temozolomide as assessed by NCI CTC v2.0 at screening, baseline, and then monthly until study completion [ Designated as safety issue: Yes ]
  • Overall quality of life as assessed by Karnofsky performance status questionnaire periodically during study [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Temozolomide in Treating Patients With Invasive Pituitary Tumors
An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Temozolomide Treatment in Patients With Invasive Pituitary Tumors

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with invasive pituitary tumors.

OBJECTIVES:

Primary

  • To assess the effect of temozolomide on pituitary tumor growth in patients with invasive pituitary tumors.
  • To assess the effect of temozolomide on pituitary tumor response and the duration of tumor response in these patients.

Secondary

  • To assess the effect of temozolomide on pituitary tumor hormone secretion in these patients.
  • To assess the effect of temozolomide on other aspects of pituitary function in these patients.
  • To assess the overall safety and tolerability of temozolomide in these patients.
  • To assess the overall quality of life of patients treated with temozolomide.

OUTLINE: This is a multicenter study.

Patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of 12 courses, patients achieving a complete or partial tumor response may continue to receive temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity.

Tumor tissue samples are collected periodically to assess methylation status of the methyl-guanine methyl-transferase promoter (MGMT) gene and to quantitate immunocytochemical expression of the tumor suppressor proteins p53, p16, and p27. Tissue samples are also analyzed by microarray and proteomics to determine a genetic "signature" of invasive vs non-invasive pituitary tumors and to determine if this signature correlates with response to temozolomide. Blood samples are also periodically for biomarker laboratory studies.

Patients complete a quality of life questionnaire periodically.

After completion of study therapy, patients are followed for 28 days.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Brain and Central Nervous System Tumors
  • Drug: temozolomide
  • Genetic: DNA methylation analysis
  • Genetic: microarray analysis
  • Genetic: protein expression analysis
  • Genetic: proteomic profiling
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
October 2010   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Clinically demonstrable invasive pituitary macroadenoma, including any of the following subtypes:

    • Growth hormone-secreting
    • Prolactin-secreting
    • Adrenocorticotrophic hormone-secreting
    • Non-secreting
  • Must have biochemical evidence of any of the following:

    • Acromegaly as measured by serum insulin-like growth factor-1 (IGF-1)
    • Prolactinoma as measured by serum prolactin (PRL)
    • Cushing's disease as measured by 24-hour urinary-free cortisol
  • Inadequate tumor control, defined as a visible pituitary tumor ≥ 1 cm in maximal diameter encasing the carotid arteries, and/or invading into the cavernous sinuses, and/or abutting/invading the optic chiasma as demonstrated by MRI scan with or without contrast
  • Previously assessed by radiosurgery and meets ≥ 1 of the following criteria:

    • Not a suitable candidate for radiotherapy (e.g., tumor abutting and/or invading the optic chiasm)
    • Declined radiotherapy (in light of side effects or personal choice)
    • Has not exhibited tumor shrinkage or tumor continues to grow ≥ 1 year after completion of radiotherapy
  • Must have a normal visual field evaluation by Goldman perimetry

    • No visual field abnormalities
  • Hypopituitarism allowed as evidenced by any or all of the following:

    • Subnormal growth hormone response to arginine/growth hormone-releasing hormone testing (normal response is an increase of > 4 ng/mL)
    • Low age- and sex-matched IGF-1 levels
    • Low thyroid-stimulating hormone (TSH), free triiodothyronine (T3), and free thyroxine (T4) levels
    • Low estradiol levels
    • Low luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in postmenopausal female patients OR low testosterone, LH, and FSH levels in male patients
    • Serum cortisol < 3 ng/mL (at 8 am)
  • Patients diagnosed with hypopituitarism (except for post-menopausal females) are required to initiate hormone replacement therapy for the 12-month duration of the study and to discontinue hormone replacement therapy at the end of 12 months to re-evaluate hypopituitarism

PATIENT CHARACTERISTICS:

  • Able to undergo a pituitary MRI scan
  • No clinically significant renal, hematologic, or hepatic abnormalities
  • No prior or concurrent medical condition that may interfere with the conduct of the study or the evaluation of its results, in the opinion of the Investigator or the Data Safety Monitoring Board compliance officer
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception for ≥ 2 months prior to, during, and for 1 month after completion of study therapy
  • No history of immunocompromise, including known HIV positivity as measured by enzyme linked immunosorbent assay (ELISA) and western blot
  • No alcohol or drug abuse within the past 6 months
  • No blood donation within the past 2 months
  • No history of noncompliance to medical regimens, potential unreliability, or inability to complete the entire study
  • No other active malignant disease within the past 5 years, except basal cell carcinoma or carcinoma in situ of the cervix
  • No active or suspected acute or chronic uncontrolled infection

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • Prior pituitary surgery allowed provided the surgery failed to induce complete tumor response and the patient is deemed unsuitable for further pituitary surgeries
  • At least 3 months since prior pituitary surgery
  • More than 1 month since prior unlicensed drugs or participation in a clinical trial with an investigational drug
  • No concurrent pituitary surgery or pituitary radiotherapy
  • No other concurrent therapy to reduce pituitary tumor size
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00601289
CDR0000577534, P30CA016042, 07-05-077-01
Yes
Not Provided
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Study Chair: Anthony Heaney, MD Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP